{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:09:12Z","timestamp":1793250552619,"version":"4.5.0"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011717","name":"Leuka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015430","name":"Anthony Nolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015430","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS Blood & Transplant"},{"DOI":"10.13039\/501100024951","name":"IMPACT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024951","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Graft-versus-host disease (GvHD) remains a major complication of allogeneic stem cell transplantation (allo-SCT), affecting 30\u201370% of patients (representing 800 new patients per year in the UK). The risk is higher in patients undergoing unrelated allo-SCT. About 1 in 10 patients die as a result of GvHD or through complications of its treatment. In patients who survive GvHD and or the complications of treatment, about 1 in 3 patients develop chronic GvHD which has a negative impact on quality of life (QoL). Many transplant protocols use alemtuzumab or anti-thymocyte globulin (ATG) in combination with a calcineurin inhibitor (CNI) and mycophenolate mofetil as GvHD prophylaxis; however, the outcomes of these treatments are complicated by high rates of infection and therefore the development of improved GvHD prophylaxis strategies represents a major unmet need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Methods of T-Cell Depletion trial is a prospective, multicentre, adaptive randomised trial in patients undergoing reduced intensity-conditioned unrelated donor allo-SCT. The trial will compare the novel GvHD prophylaxis regimens post-transplant cyclophosphamide (PTCy) in combination with a CNI or sirolimus (PTCy-CNI or PTCy-sirolimus, respectively) to a current standard-of-care GvHD prophylaxis involving the use of Thymoglobulin (a specific brand of ATG containing rabbit polyclonal antibodies). The primary outcome measure is GvHD-free, relapse-free survival at 1 year. Secondary outcomes include cumulative incidence of acute grade II-IV GvHD at 1 year, cumulative incidence of moderate and severe chronic GvHD at 1\u2009year, overall survival at 1 year and cumulative incidence of non-relapse mortality at 1\u2009year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the West Midlands, Edgbaston Research Ethics Committee (20\/WM\/0195); initial approval was received on 11 September 2020, current protocol version (V.4.0) approval on 25 July 2023. The Medicines and Healthcare products Regulatory Authority also approved all protocol versions. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EudraCT Number: 2019-002419-24.<\/jats:p>\n                    <jats:p>ISRCTN Number: 50290131.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-086223","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:56:51Z","timestamp":1738112211000},"page":"e086223","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)"],"prefix":"10.1136","volume":"15","author":[{"given":"Ronjon","family":"Chakraverty","sequence":"first","affiliation":[{"name":"Haematology, Oxford Cancer and Haematology Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kempshall","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Dignan","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Manchester Royal Infirmary, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"Haematology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Newcastle Freeman Hospital, High Heaton Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Davies","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Queen Mary University London Charterhouse Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Potter","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[{"name":"Haematology, Addenbrooke's Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Smith","sequence":"additional","affiliation":[{"name":"Pharmacy, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gates","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"},{"name":"Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gaskell","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bishop","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-7650","authenticated-orcid":false,"given":"Andrea","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Smith","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2025120618270453000_15.1.e086223.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337"},{"key":"2025120618270453000_15.1.e086223.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703472"},{"key":"2025120618270453000_15.1.e086223.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"2025120618270453000_15.1.e086223.4","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025120618270453000_15.1.e086223.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00462-3"},{"key":"2025120618270453000_15.1.e086223.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8177"},{"key":"2025120618270453000_15.1.e086223.7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124218"},{"key":"2025120618270453000_15.1.e086223.8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2021015129","article-title":"How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"key":"2025120618270453000_15.1.e086223.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943"},{"key":"2025120618270453000_15.1.e086223.10","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"2025120618270453000_15.1.e086223.11","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025120618270453000_15.1.e086223.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02293"},{"key":"2025120618270453000_15.1.e086223.13","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025120618270453000_15.1.e086223.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004383"},{"key":"2025120618270453000_15.1.e086223.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506002"},{"key":"2025120618270453000_15.1.e086223.16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2024","journal-title":"Br J Haematol"},{"key":"2025120618270453000_15.1.e086223.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-418202"},{"key":"2025120618270453000_15.1.e086223.18","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","article-title":"Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant","volume":"7","author":"P\u00e9rez-Valencia","year":"2023","journal-title":"Blood Adv"},{"key":"2025120618270453000_15.1.e086223.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-086223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:27:16Z","timestamp":1765074436000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-086223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-086223"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-086223","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}